C Diff Drug Development

@Khanna_S summarizing bezlotoxumab and #FMT pic.twitter.com/KwypHDwF1w— John Damianos, M.D. (@john_damianosMD) October 23, 2022

SOMERVILLE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery ® platform to develop a novel class of orally administered biological drugs,

SOMERVILLE, Mass., Oct. 24, 2022 (GLOBE NEWSWIRE) -- Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage...

CAMBRIDGE, Mass., October 23, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, announces the presentation of safety and efficacy data from its open-label Phase 3 ECOSPOR IV extension study evaluating investigational oral microbiome therapeutic SER-109 for the prevention of rCDI at the IDWeek 2022 and American College of Gastroenterology (ACG) 2022 Annual Meetings. Among the ECOSPOR IV study participants, many of whom have multiple comorbidities, SER-109 w

CAMBRIDGE, Mass., October 19, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced the publication of Phase 3 clinical data in the Journal of the American Medical Association (JAMA), highlighting that the clinical benefits of investigational therapeutic SER-109 for preventing recurrent C. difficile infection (rCDI) were apparent as early as two weeks post-treatment and sustained for at least 24 weeks.

Clostridium Difficile Infections pipeline constitutes 25+ key companies continuously working towards developing 25+ Clostridium Difficile Infections treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. Clostridium Difficile Infections Overview Clostridium Difficile Infections, also known as Clostridioides difficile or C. difficile is a type of bacteria that causes […]

Extended Follow-up of Microbiome Therapeutic SER-109 Through 24 Weeks for Recurrent Clostridioides difficile Infection in a Randomized Clinical Trial

Tomorrow at 8:40 AM ET, Acurx Pharmaceuticals' will present a poster on Ibezapolstat, the Company's investigative therapy designed to treat patients with #CDiff at @IDWeek2022. For details: https://t.co/khD0p15Pme #IDWeek2022— Antimicrobials Working Group (@AWG_News) October 19, 2022

The investigational microbiota-based live biotherapeutic, which was endorsed by the FDA's Vaccines and Related Biological Products Advisory Committee at the end of ...

An optimally operating microbiome supports protective, metabolic, and immune functions, but disruptions produce metabolites and toxins which can be involved in many conditions. Probiotics have the ...

The investigational microbiota-based live biotherapeutic, which was endorsed by the FDA's Vaccines and Related Biological Products Advisory Committee at the end of ...

.@SeresTX's microbiome therapeutics represent an entirely new class of potential medicines with promise across a wide range of diseases including #CDiff, ulcerative colitis, #AMR infections & GvHD and metastatic #melanoma. Read more: https://t.co/5eSOyNFkV1— MTIG (@MTIG_News) October 13, 2022

Menlo Park, California, Oct. 13, 2022 (GLOBE NEWSWIRE) -- Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) and its product...

RBX2660 is a standardized, stabilized, investigational microbiota-based live biotherapeutic.

The Investor Relations website contains information about Seres Therapeutics's business for stockholders, potential investors, and financial analysts.

Acurx Pharmaceuticals was getting bullish interest at over $4.00. Now at $3.40ish, the herd should be pouncing. The interest is in ACXP's ibezapolostat, a novel, orally administered antibiotic being... | October 11, 2022

Acurx Pharmaceuticals was getting bullish interest at over $4.00. Now at $3.40ish, the herd should be pouncing. The interest is in ACXP’s ibezapolostat, a novel, orally administered antibiotic being developed as a Gram-Positive Selective Spectrum (GPSS™) antibacterial. While many potential new drugs show potential, this one can indeed be a game-changer in treating debilitating infections. […]

DelveInsight’s, “Clostridium Difficile Infections Pipeline Insight, 2022” report provides comprehensive insights about 25+ companies and 25+ pipeline drugs in Clostridium Difficile Infections (Clostridium Difficile Associated Disease) pipeline landscape.   Clostridium Difficile Infections Pipeline Insight, 2022″ report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the […]

Nature Reviews Drug Discovery - Discover the world’s best science and medicine | Nature.com

#ClostridioidesDifficile #cdiff— Wiep Klaas Smits (@SmitsLab) October 7, 2022

Drs Feuerstadt, Abraham, and Chopra discuss clinical trial data for RBX2660, a live biotherapeutic product, in treatment of recurrent C difficile infection (rCDI), as well as data with RBX2660 that were presented at DDW 2022.

Drs Feuerstadt, Abraham, and Chopra discuss clinical trial data for RBX2660, a live biotherapeutic product, in treatment of recurrent C difficile infection (rCDI), as well as data with RBX2660 that were presented at DDW 2022.